Alumis: Could This Broken Immunology IPO Become The Next Amgen?
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...
IGM Biosciences, Inc.: IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus - - Mary Beth ...
Zacks.com on MSN9h
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...
bovnews12h
Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Crain's New York13h
Big pharma companies layoff hundreds amid tepid sales and legal battles
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Investor's Business Daily on MSN15h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Bristol-Myers wins FDA nod for Opdivo lung cancer indication
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
2 Passive Income Stocks to Load Up On in October
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...